Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field
AbstractThe ability to create patient derived xenografts (PDXs) has evolved considerably from the breakthrough of the development of immune compromised mice. How researchers in drug discovery have utilized PDX of certain cancer types has also changed from traditionally selecting a few models to profile a drug, to opting to assess inter-tumor response heterogeneity by screening across a broad range of tumor models, and subsequently to enable clinical stratification strategies. As with all models and methodologies, imperfections with this approach are apparent, and our understanding of the fidelity of these models continues to expand. To date though, they are still viewed as one of the most faithful modeling systems in oncology. Currently, there are many efforts ongoing to increase the utility and translatability of PDXs, including introducing a human immune component to enable immunotherapy studies. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Williams, J.A. Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field. J. Clin. Med. 2018, 7, 41.
Williams JA. Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field. Journal of Clinical Medicine. 2018; 7(3):41.Chicago/Turabian Style
Williams, Juliet A. 2018. "Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field." J. Clin. Med. 7, no. 3: 41.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.